Insider Selling: Magellan Health Inc (MGLN) Insider Sells 59,313 Shares of Stock
Magellan Health Inc (NASDAQ:MGLN) insider Clapper Caskie Lewis sold 59,313 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $93.99, for a total value of $5,574,828.87. Following the completion of the sale, the insider now owns 48,474 shares of the company’s stock, valued at approximately $4,556,071.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Magellan Health Inc (NASDAQ:MGLN) traded up $0.45 during trading hours on Tuesday, hitting $95.70. The company had a trading volume of 173,921 shares, compared to its average volume of 143,662. The company has a current ratio of 2.28, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62. Magellan Health Inc has a twelve month low of $64.05 and a twelve month high of $95.90. The stock has a market capitalization of $2,146.98, a price-to-earnings ratio of 20.34, a price-to-earnings-growth ratio of 1.15 and a beta of 0.54.
Magellan Health (NASDAQ:MGLN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $1.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.40 by $0.24. Magellan Health had a return on equity of 9.20% and a net margin of 1.68%. The business had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company earned $1.39 earnings per share. Magellan Health’s quarterly revenue was up 9.9% compared to the same quarter last year. sell-side analysts anticipate that Magellan Health Inc will post 5.19 earnings per share for the current fiscal year.
A number of analysts have recently issued reports on MGLN shares. BidaskClub upgraded Magellan Health from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. ValuEngine upgraded Magellan Health from a “hold” rating to a “buy” rating in a report on Friday, September 1st. KeyCorp restated a “buy” rating and issued a $89.00 target price on shares of Magellan Health in a report on Friday, September 22nd. Zacks Investment Research lowered Magellan Health from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, Jefferies Group restated a “buy” rating and issued a $94.00 target price on shares of Magellan Health in a report on Friday, October 13th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $90.50.
ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/05/insider-selling-magellan-health-inc-mgln-insider-sells-59313-shares-of-stock.html.
About Magellan Health
Magellan Health, Inc is engaged in the healthcare management business. The Company’s segments include Healthcare, Pharmacy Management and Corporate. It is focused on managing special populations, complete pharmacy benefits and other specialty areas of healthcare. Its Healthcare includes its management of behavioral healthcare services and employee assistance program (EAP) services, management of other specialty areas, including diagnostic imaging and musculoskeletal management, and the integrated management of physical, behavioral and pharmaceutical healthcare for special populations, delivered through Magellan Complete Care (MCC).
Receive News & Ratings for Magellan Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.